Aligning Estimators With Estimands in Clinical Trials: Putting the ICH E9(R1) Guidelines Into Practice

被引:0
|
作者
C. H. Mallinckrodt
J. Bell
G. Liu
B. Ratitch
M. O’Kelly
I. Lipkovich
P. Singh
L. Xu
G. Molenberghs
机构
[1] Biogen,
[2] Elderbrook Solutions GmbH,undefined
[3] Merck Research Laboratories,undefined
[4] Eli Lilly,undefined
[5] IQVIA,undefined
[6] Novartis,undefined
[7] Vertex Pharmaceuticals,undefined
[8] I-BioStat,undefined
[9] Universiteit Hasselt and KU Leuven,undefined
关键词
estimands; estimation; missing data; sensitivity;
D O I
暂无
中图分类号
学科分类号
摘要
The draft ICH E9(R1) addendum stipulates that an estimator should align with its associated estimand and yield an estimate that facilitates reliable interpretations. The addendum further stipulates that assumptions should be justifiable and plausible, and that the extent of assumptions is an important consideration for whether an estimate will be robust because assumptions are often unverifiable. The draft addendum specifies 5 strategies for dealing with intercurrent events. The intent of this paper is to provide conceptual considerations and technical details for various estimators that align with these strategies. We include focus on how the nature and extent of assumptions influences the potential robustness of the various estimators. The content reflects the knowledge, experience, and opinions of the Drug Information Association’s Scientific Working Group on Missing Data. This group includes experienced statisticians from across industry and academia, primarily in the US and European Union.
引用
收藏
页码:353 / 364
页数:11
相关论文
共 27 条
  • [1] Aligning Estimators With Estimands in Clinical Trials: Putting the ICH E9(R1) Guidelines Into Practice
    Mallinckrodt, C. H.
    Bell, J.
    Liu, G.
    Ratitch, B.
    O'Kelly, M.
    Lipkovich, I
    Singh, P.
    Xu, L.
    Molenberghs, G.
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2020, 54 (02) : 353 - 364
  • [2] Choosing Estimands in Clinical Trials: Putting the ICH E9(R1) Into Practice
    Bohdana Ratitch
    James Bell
    Craig Mallinckrodt
    Jonathan W. Bartlett
    Niti Goel
    Geert Molenberghs
    Michael O’Kelly
    Pritibha Singh
    Ilya Lipkovich
    Therapeutic Innovation & Regulatory Science, 2020, 54 : 324 - 341
  • [3] Choosing Estimands in Clinical Trials: Putting the ICH E9(R1) Into Practice
    Ratitch, Bohdana
    Bell, James
    Mallinckrodt, Craig
    Bartlett, Jonathan W.
    Goel, Niti
    Molenberghs, Geert
    O'Kelly, Michael
    Singh, Pritibha
    Lipkovich, Ilya
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2020, 54 (02) : 324 - 341
  • [4] Defining Efficacy Estimands in Clinical Trials: Examples Illustrating ICH E9(R1) Guidelines
    Bohdana Ratitch
    Niti Goel
    Craig Mallinckrodt
    James Bell
    Jonathan W. Bartlett
    Geert Molenberghs
    Pritibha Singh
    Ilya Lipkovich
    Michael O’Kelly
    Therapeutic Innovation & Regulatory Science, 2020, 54 : 370 - 384
  • [5] Defining Efficacy Estimands in Clinical Trials: Examples Illustrating ICH E9(R1) Guidelines
    Ratitch, Bohdana
    Goel, Niti
    Mallinckrodt, Craig
    Bell, James
    Bartlett, Jonathan W.
    Molenberghs, Geert
    Singh, Pritibha
    Lipkovich, Ilya
    O'Kelly, Michael
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2020, 54 (02) : 370 - 384
  • [6] The estimands framework: a primer on the ICH E9(R1) addendum
    Kahan, Brennan C.
    Hindley, Joanna
    Edwards, Mark
    Cro, Suzie
    Morris, Tim P.
    BMJ-BRITISH MEDICAL JOURNAL, 2024, 384
  • [7] Estimands in observational studies: Some considerations beyond ICH E9 (R1)
    Li, Heng
    Wang, Chenguang
    Chen, Wei-Chen
    Lu, Nelson
    Song, Changhong
    Tiwari, Ram
    Xu, Yunling
    Yue, Lilly Q.
    PHARMACEUTICAL STATISTICS, 2022, 21 (05) : 835 - 844
  • [8] Application of estimand framework in ICH E9 (R1) to vaccine trials
    Fu, Rong
    Li, Hal
    Wang, Xuelong
    Shou, Qiong
    Wang, William W. B.
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2023, 33 (04) : 502 - 513
  • [9] Clinical and Statistical Perspectives on the ICH E9(R1) Estimand Framework Implementation
    Ionan, Alexei C.
    Paterniti, Miya
    Mehrotra, Devan, V
    Scott, John
    Ratitch, Bohdana
    Collins, Sylva
    Gomatam, Shanti
    Nie, Lei
    Rufibach, Kaspar
    Bretz, Frank
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2023, 15 (03): : 554 - 559
  • [10] ASSESSING THE RISK OF BIAS IN CLINICAL TRIALS FOR HEALTH TECHNOLOGY ASSESSMENTS: SHOULD EXISTING TOOLS REFLECT THE ICH E9(R1) ADDENDUM ON ESTIMANDS AND SENSITIVITY ANALYSES?
    Poythress, J.
    Morga, A.
    VALUE IN HEALTH, 2023, 26 (12) : S329 - S329